2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4276 Cancer screening and skeletal surveillance patterns among long-term survivors of allogeneic hematopoietic cell transplantation: A propensity score-matched real-world analysis

Kanishka Uttam Chandani, M.B.B.S., Jatin Thukral, MD2, Akshaya Keerti, MD3, Ruth Ayala, APRN, CNP, MSN4, Diana Zamora, MD5, Usman Ilyas6, Ali Hassan, MD7, Bhavi Trivedi, MD8, Saurabh Chhabra, MD, MBBS9, Lisa Sproat, M.D.10, Nathan Punwani, M.D.11, Jeanne Palmer, MD12, Nandita Khera, MD13, Shahrukh Hashmi14, Talal Hilal, MD15
1 Mayo Clinic, Phoenix, Arizona, United States
2 New York Medical College/Landmark Medical Center, Woonsocket, Rhode Island, United States
3 Appalachian Regional Healthcare, Whitesburg, Kentucky, United States
4 Mayo Clinic, Phoenix, Arizona, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Phoenix, Arizona, United States
7 Mayo Clinic, Phoenix, Arizona, United States
8 Texas Tech University Health Science Center, El Paso, Texas, United States
9 Mayo Clinic, Phoenix, Arizona, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 Mayo Clinic, Phoenix, Arizona, United States
12 Mayo Clinic, Phoenix, Arizona, United States
13 Mayo Clinic, Phoenix, Arizona, United States
14 Department of Health, Abu Dhabi, United Arab Emirates, MBZUAI, Abu Dhabi, United Arab Emirates
15 Mayo Clinic, Phoenix, Arizona, United States

Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for a range of benign and malignant hematologic conditions. However, it is associated with numerous late effects, including second cancers, infections, osteoporosis, and chronic illnesses that can affect any organ system. This necessitates a robust surveillance strategy, particularly in an era in which responsibility for survivorship care is increasingly shared with community oncologists and primary care providers. We evaluated adherence to recommended cancer screening and skeletal surveillance among long-term allo-HCT survivors compared with matched non-transplanted patients with hematologic malignancies.

Methods:  We performed a retrospective, propensity score-matched cohort study in the TriNetX Research Network, a federated network providing de-identified EMR data from 116 healthcare organizations. Adults undergoing allo-HCT between 2010 and 2021, identified by procedure codes without a required hematologic diagnosis, who survived at least 5 years after transplantation were compared with non-transplanted patients with AML, MDS, or MPN who also reached a 5-year landmark after diagnosis. Both cohorts required a documented visit at age >=45 years at their respective landmark and no recorded death; this landmark visit served as the index date. Cohorts were matched 1:1 on age at index, sex, race, ethnicity, and underlying hematologic diagnoses (all standardized differences <0.05). Outcomes were assessed over a single window opening 2 years after the index visit and closing 8 years later (i.e., at least 7-15 years after transplantation or diagnosis, respectively); follow-up was censored at the last recorded encounter, and patients were not required to remain under observation throughout. Outcomes were breast and colorectal cancer screening; bone densitometry; skin biopsy; fracture; incident site-specific cancers; and new malignant neoplasms. The breast cancer analysis was restricted to women. Patients with the relevant cancer recorded before the window opened were excluded from the three site-specific incident cancer endpoints, but not from the fracture, skin biopsy, bone densitometry, or new malignant neoplasm analyses. Screening and procedural utilization were analyzed using risk ratios (RR), and clinical outcomes were analyzed using Cox hazard ratios (HR) with log-rank tests.

Results: Among women (1,692 matched pairs; median age 61 years, IQR 14), mammography was less frequent after allo-HCT than in matched controls (14.5% vs 19.2%; RR 0.754, 95% CI 0.648-0.877, p<0.001), while incidence of breast cancer was similar (HR 0.972, 95% CI 0.498-1.899, log-rank p=0.935). Because mammography is recommended at 1- to 2-year intervals, the 8-year window afforded four to eight opportunities per woman, leaving most women in both arms unscreened. In 3,775 matched pairs (median age 62 years, IQR 14), colorectal cancer screening was also significantly lower (5.3% vs 12.8%; RR 0.412, 95% CI 0.352-0.483, p<0.001), with no difference in colorectal cancer incidence (HR 1.583, 95% CI 0.729-3.437, log-rank p=0.242). 

In contrast, bone densitometry was more frequent among survivors (11.8% vs 8.7%; RR 1.361, 95% CI 1.188-1.558, p<0.001), and fractures were fewer (3.0% vs 4.7%; HR 0.770, 95% CI 0.607-0.977, log-rank p=0.031). Skin biopsy did not differ (5.3% vs 4.5%; RR 1.182, 95% CI 0.969-1.443, p=0.099), nor did skin cancer (2.0% vs 2.6%; HR 1.031, 95% CI 0.744-1.427, log-rank p=0.856). New malignant neoplasms occurred at an equivalent overall rate (12.7% vs 12.8%) but accrued earlier among survivors (HR 1.194, 95% CI 1.052-1.356, log-rank p=0.006).

Conclusion: Long-term allo-HCT survivors received less age-appropriate cancer screening than matched non-transplanted survivors, with comparable overall cancer incidence. In contrast, skeletal surveillance was more frequent and associated with fewer fractures. These findings highlight important gaps in preventive survivorship care after allo-HCT and underscore the need for stronger coordination between transplant programs, oncology, and primary care to improve screening delivery. Further studies are needed to better understand this gap and to help create strategies to address it.

Kanishka Uttam Chandani, M.B.B.S.: No relevant conflicts of interest to declare.